News & Events
-
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted...
-
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects... -
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum... -
KRAS Virtual Meetup
Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. After registering, you will receive a confirmation email... -
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung... -
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are learning how to... -
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2...
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted by the International Association for the Study of Lung Cancer, this annual gathering was held in Huntington Beach, California from Feb. 18-21, 2026. It has become known as one of the key meetings for participants to discuss the latest breakthroughs and challenges in lung cancer.This year’s meeting…
The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer
The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer
Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report
Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report
Investigators from Tianjin Medical University Target Personalized Medicine (A Ct Imaging-based Deep Learning Model for Predicting Egfr and Kras Mutations In Non-small Cell Lung Cancer:...
Investigators from Tianjin Medical University Target Personalized Medicine (A Ct Imaging-based Deep Learning Model for Predicting Egfr and Kras Mutations In Non-small Cell Lung Cancer:...
Selinexor and Docetaxel Indicate Promise in KRAS-Mutant NSCLC
Cetuximab Boosts KRAS G12C Inhibitors in Lung Cancer
UK's NICE Does Not Recommend Lumakras for KRAS G12C-Mutant NSCLC, Asks for More Data
和誉医药口服小分子KRAS G12D抑制剂ABSK141完成首例患者给药
Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series
Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series
Findings from University of Malakand Provide New Insights into Computational Biophysics and Chemistry (Transfiguring Novel Marine Natural Product As Oncogenic Kras G12c Mutant Inhibitors Via...
Findings from University of Malakand Provide New Insights into Computational Biophysics and Chemistry (Transfiguring Novel Marine Natural Product As Oncogenic Kras G12c Mutant Inhibitors Via...
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC - IASLC
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a sobering reminder that our work is far from over.The Big Picture Shows Real ProgressLet’s start with the good news. We have made significant strides in cancer care over the past three decades. Since 1991, the cancer death rate has dropped by 34%. This translates to approximately 4.8 million…
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions.AI has evolved from early consumer tools (like autocorrect on phones, customer service chatbots, and personalized shopping recommendations) to advanced systems with the potential to revolutionize biomedical discovery and patient care. While there is tremendous excitement around AI, there is also a critical need to use it responsibly.Researchers are actively…
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting healthy tissue. But sometimes, the checks and balances get confused and stop the immune system from doing what’s right—such as killing tumor cells. Tumor cells are good at confusing the immune system because they originate from our healthy cells. They can often avoid detection by immune cells. Through several…
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused on multidisciplinary research aiming to leverage the immune system to improve outcomes for cancer patients, including several exciting areas of growth in lung cancer-directed immunotherapy.Tumor Imaging is Growing More Powerful Advanced imaging techniques are poised to change how we understand and treat…
The Future of Lung Cancer Starts Here
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity.Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the…
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum—from early detection to treating advanced disease.“Today’s research is tomorrow’s cure. If we want to see continued breakthroughs and advancements in lung cancer, we must secure a strong pipeline of researchers dedicated to improving outcomes for people with lung cancer,” said Upal Basu Roy, PhD, MPH, Executive Director…
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community.Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made…
Veteran Voices: Surgery to Survivorship at the VA
Veteran Voices: Surgery to Survivorship at the VA
Last November, Michael O’Donnell was at the Dallas VA during Lung Cancer Awareness Month. It’s where he receives treatment for his lung cancer, but on this specific day, he was joined by LUNGevity staff to talk with veterans about screening.“My job was easy. I was at a table with Kristi Griffith [LUNGevity’s Survivorship Navigator] so that I could answer questions as someone who uses the VA to get treated for lung cancer,” says Michael. Michael is a veteran of the Vietnam War and uses the…
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are learning how to optimize existing therapies and are exploring entirely new treatment approaches. At the 2025 World Conference on Lung Cancer (WCLC), several studies highlighted progress in treating newly diagnosed individuals as well as those who need new options after standard therapies stop working. Combining Chemotherapy and…
6 Tips for Managing Scanxiety
6 Tips for Managing Scanxiety
Read time: 4 minutes.Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as well as “what if” thoughts focused on receiving bad news, like the return or growth of a cancerous tumor. Scanxiety can be intense and intrusive, and you might find it difficult to focus on other thoughts or tasks. Many people, especially those who did not experience anxiety prior to their diagnosis, might feel…
Why Do Some People Who Have Never Smoked Get Lung Cancer?
Why Do Some People Who Have Never Smoked Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure.Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this…
2025 ASCO: Highlights of Lung Cancer Research
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2, researchers, oncologists, and patient advocates had first-hand access to the latest cancer research news. The theme for the 2025 ASCO conference was “Driving Knowledge to Action: Building a Better Future.” This theme was represented through several presentations during the conference that showcased how the cancer…
Surviving LMD: Michelle Never Settled for “No”
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue, however, is that LMD is so rare—only diagnosed in 5% of people with cancer—she had to advocate for the testing to prove it.“I called my clinic and said I needed a brain MRI because I think I have LMD. They didn’t want to schedule one, so I said, tell my doctor I’m demanding a brain MRI. I can tell him directly if I…
Watch HOPE Summit Videos
Watch HOPE Summit Videos
HOPE Summit 2025 was filled with messages of hope, meeting new and hugging old friends, and of course the inspirational and informative sessions that help people live well with lung cancer. For the first time ever, select sessions were recorded for those who weren’t able to attend, and for those who did attend to rewatch what resonated. View the entire collection here or see below for the sessions you want to watch.HOPE Summit 2025 Recorded SessionsKeynote: Breathing Beyond Boundaries…
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
What Is Integrative Oncology? Integrative oncology is the use of complementary therapies alongside conventional lung cancer treatments like chemotherapy, targeted therapy, surgery, or immunotherapy. Integrative oncology—also called integrative medicine—is an evidence-informed whole-body approach to health. It is often used to address symptoms and side effects caused by disease or treatment and improve overall quality of life. Specific examples of integrative oncology for lung cancer…
What Should Patients Know About Lung Cancer Surgery?
What Should Patients Know About Lung Cancer Surgery?
Surgery is a treatment option for early-stage lung cancer that involves removing all or part of a lung to treat a cancerous tumor. It is primarily an option for people with non-small cell lung cancer (NSCLC) staged at I, II, or IIIA. Surgery is rarely considered for tumors at stage IIIB or IV because those lung cancers have spread to other parts of the body. It is also rarely used to treat small cell lung cancer (SCLC) because SCLC is typically diagnosed at a later stage. Types of…
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center…
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Rasheed Marshall understands the secondhand effects of cancer well. First his mom, Joycelyn, was diagnosed with breast cancer in 1995. It came back in 2015 and eventually metastasized (spread) to her lungs. Soon after, his brother-in-law Romain was diagnosed with brain cancer. They both passed away the same week. “It was tough for the entire family when we learned mom’s cancer came back. She didn’t want to go through treatment again—which is why she didn’t tell us about it right away—so…
Staying Safe From Smoke, Pollution, and Dangerous Air Quality
Staying Safe From Smoke, Pollution, and Dangerous Air Quality
On the West Coast, wildfires are taking human lives and destroying homes. On the East Coast, the devastating results of Hurricane Helene are leading to illegal open burning of debris and trash. Thousands of miles separate these fires, but the results are the same—dangerous particles are entering the air we breathe. LUNGevity spoke with Angela Hopper, an 11-year lung cancer survivor who spent 30 years working as an air quality specialist at the North Carolina Department of Environmental…